Editas Medicine, Inc. (NASDAQ:EDIT) Financial Analysis

Editas Medicine's ROIC is significantly lower than its WACC, indicating poor capital efficiency.Compared to peers, CRISPR Therapeutics shows the least negative ROIC to WACC ratio, suggesting better capital management.All companies in the gene editing space, including Beam Therapeutics and Pacific Biosciences, face challenges in generating returns above their cost of capital.Editas Medicine, Inc. (NASDAQ:EDIT) is a biotechnology company focused on developing gene editing technologies. The company aims to tra ...